Kyle Rose

Stock Analyst at Canaccord Genuity

(2.66)
# 2,218
Out of 5,090 analysts
114
Total ratings
53.26%
Success rate
13.71%
Average return

Stocks Rated by Kyle Rose

Smith & Nephew
Feb 26, 2025
Maintains: Hold
Price Target: $27
Current: $33.48
Upside: -19.35%
Insulet
Feb 21, 2025
Maintains: Buy
Price Target: $304$324
Current: $304.49
Upside: +6.41%
Stryker
Jan 29, 2025
Maintains: Buy
Price Target: $420$435
Current: $364.02
Upside: +19.50%
Globus Medical
Dec 20, 2023
Maintains: Buy
Price Target: $67$71
Current: $91.10
Upside: -22.06%
Enovis
Dec 20, 2023
Maintains: Buy
Price Target: $65$71
Current: $27.02
Upside: +162.77%
InMode
Oct 13, 2023
Downgrades: Hold
Price Target: $55$22
Current: $14.42
Upside: +52.57%
The Beauty Health Company
Aug 25, 2023
Assumes: Buy
Price Target: $10
Current: $1.46
Upside: +584.93%
Alphatec Holdings
Aug 4, 2023
Maintains: Buy
Price Target: $17$22
Current: $21.45
Upside: +2.56%
DexCom
Jul 28, 2023
Maintains: Buy
Price Target: $135$150
Current: $65.49
Upside: +129.04%
Vicarious Surgical
May 31, 2023
Maintains: Buy
Price Target: $360$270
Current: $2.98
Upside: +8,960.40%
Maintains: Buy
Price Target: $24$27
Current: $19.68
Upside: +37.20%
Reiterates: Buy
Price Target: $15
Current: $1.15
Upside: +1,204.35%
Reiterates: Buy
Price Target: $15
Current: $33.32
Upside: -54.98%
Maintains: Market Perform
Price Target: $125$122
Current: $157.82
Upside: -22.70%
Upgrades: Buy
Price Target: $3$4
Current: $5.57
Upside: -28.19%
Downgrades: Hold
Price Target: n/a
Current: $7.09
Upside: -
Downgrades: Hold
Price Target: $165$125
Current: $94.28
Upside: +32.58%